| Dr Rodger Allen Lindsey, DC | |
|
247 Mohawk Street, Brownsville, KY 42210-0479 | |
| (270) 597-9024 | |
| (270) 597-9024 |
| Full Name | Dr Rodger Allen Lindsey |
|---|---|
| Gender | Male |
| Speciality | Chiropractor |
| Location | 247 Mohawk Street, Brownsville, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679666143 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 3915 (Kentucky) | Primary |
| 111N00000X | Chiropractor | 1247 (Alabama) | Secondary |
| 225700000X | Massage Therapist | KY-0933 (Kentucky) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rodger Allen Lindsey, DC Po Box 479, Brownsville, KY 42210-0479 Ph: (270) 597-9024 | Dr Rodger Allen Lindsey, DC 247 Mohawk Street, Brownsville, KY 42210-0479 Ph: (270) 597-9024 |
News Archive
Aluminium - the most abundant metal and third most abundant element of the Earth's crust - has no known biological function and is a recognised environmental toxin. Human exposure to aluminium is implicated in a number of chronic diseases, including bone disease, auto-immune conditions, cancer and neurodegenerative diseases.
A new study published in the Journal of the American Geriatrics Society reveals that brief cognitive screenings combined with offering further evaluation increased new diagnoses of cognitive impairment in older veterans two to three fold.
pHase Pharmaceuticals, LLC announces the launch of its new drug development company. pHase Pharmaceuticals is led by a cohesive team of drug development experts who have extensive experience bringing new drugs to market and garnering FDA approval.
The 2009 swine H1N1 flu pandemic — responsible for more than 17,000 deaths worldwide — originated in pigs from a very small region in central Mexico, a research team headed by investigators at the Icahn School of Medicine at Mount Sinai is reporting.
Albumedix Ltd. ('Albumedix'), a recognized global leader in recombinant human albumin specializing in the enablement of advanced therapies, announces the completed expansion of the company's commercial-scale manufacturing facility, alongside with the establishment of a new Technology Centre equipped with state-of-the-art laboratories at its UK-based campus in Nottingham.
› Verified 5 days ago